key: cord-0431197-z86dvdg3 authors: MISHRA, B. K.; Bhattacharya, D.; Kshatri, J. S.; Pati, S. title: Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants date: 2021-07-19 journal: nan DOI: 10.1101/2021.07.19.21260302 sha: 8585e09c47427e991595bfe495d313cb59fff9f4 doc_id: 431197 cord_uid: z86dvdg3 Conflicting reports on the persistence of antibody levels in individuals recovered from COVID-19 infection, suggest that the immunity against COVID-19 may not be lasting for long. In India, by 30th June, 2021, not less than 30 million people were infected with COVID-19 and 0.39 million people were reported to have lost their life to the disease in India. I the current study we followed up with a subsample of our previous sero-survey participants to assess whether natural immunity against SARS-CoV-2 was associated with a reduced risk of re-infection. We conducted telephonic interview of a total of 3038 participants, out of which 2238 participants responded and 5 participants were found to be not alive, as conveyed by their close relatives. There was a non-response rate of 26.1%. Out of the 2238 participants, 1170 were sero-positive and 1068 were sero-negative for antibody against COVID-19. Our survey found that only 3 individuals in the sero-positive group got infected with COVID-19 whereas 127 individuals reported contracting the infection the sero-negative group. Interestingly, from the 127 sero-negative individuals who later contracted COVID-19 infection, 30 needed hospitalization, out of which 12 were on oxygen therapy, four in ICU and one was on ventilator. At the other hand, from the 3 sero-positives re-infected with COVID-19, one had hospitalization, but didnnot require oxygen support or critical care. These findings reinforce the strong plausibility that development of antibody following natural infection not only protects against re-infection by the virus to a great extent, but also safeguards against progression to severe COVID-19 disease. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A b s t r a c t : C o n f l i c t i n g r e p o r t s o n t h e p e r s i s t e n c e o f a n t i b o d y l e v e l s i n i n d i v i d u a l s r e c o v e r e d f r o m C O V I D -1 9 i n f e c t i o n , s u g g e s t t h a t t h e i m m u n i t y a g a i n s t C O V I D -1 9 m a y n o t b e l a s t i n g f o r l o n g . I n I n d i a , b y 3 0 t h J u n e , 2 0 2 1 , n o t l e s s t h a n 3 0 m i l l i o n p e o p l e w e r e i n f e c t e d w i t h C O V I D -1 9 a n d 0 . 3 9 m i l l i o n p e o p l e w e r e r e p o r t e d t o h a v e l o s t t h e i r l i f e t o t h e d i s e a s e i n I n d i a . I t h e c u r r e n t s t u d y w e f o l l o w e d u p w i t h a s u b s a m p l e o f o u r p r e v i o u s s e r o -s u r v e y p a r t i c i p a n t s t o a s s e s s w h e t h e r n a t u r a l i m m u n i t y a g a i n s t S A R S -C o V -2 w a s a s s o c i a t e d w i t All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. W e c o n d u c t e d t e l e p h o n i c i n t e r v i e w o f a t o t a l o f 3 0 3 8 p a r t i c i p a n t s s e l e c t e d f r o m o u r p r e v i o u s s e r o s e r v e y c o h o r t f r o m d i f f e r e n t d i s t r i c t o f O d i s h a . D a t a w a s r e c o r d e d i n p r e f o r m e d q u e s t i o n n a i r e . C o n s e n t w a s o b t a i n e d p r i o r t o t h e i r e n r o l l m e n t i n t h e s t u 5 I n t e r e s t i n g l y , f r o m t h e 1 2 7 s e r o -n e g a t i v e i n d i v i d u a l s w h o l a t e r c o n t r a c t e d C O V I D -1 9 i n f e c t i o n , 3 0 n e e d e d h o s p i t a l i z a t i o n , o u t o f w h i c h 1 2 w e r e o n o x y g e n t h e r a (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. D a t a a v a i l a b i l i t y A l l d a t a i n t h e m a n u s c r i p t a r e a v a i l a b l e o n r e q u e s t t o t h e c o r r e s p o n d i n g a u t h o Seroprevalence of and risk factors associated with SARS-CoV-2 infection in Health Care Workers during the early COVID-19 Pandemic in Italy IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans Ministry of Health and Family Welfare, Government of India (COVID-19) Dashboard Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.19.21260302 doi: medRxiv preprint 6. Hall, V. J. et al. SARS-CoV-2 infection rates of antibody-positive compared with antibodynegative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.19.21260302 doi: medRxiv preprint